Importance of FDA Approval

The approved formula that’s never been duplicated.

  • Helps control signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.1
  • Enters the joints quickly, within 2 hours, to help control signs of arthritis.1
  • Therapeutic concentrations in synovial fluid and articular cartilage last up to 3 days.1

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan Canine scientist in lab

What does Adequan® Canine have to offer?


Adequan Canine product comparatives chart


Understanding the significance of FDA approval.

Whether you are a veterinarian or pet owner, understanding the differences between your choices is important. For a new veterinary drug to satisfy each stage of the FDA approval process often takes years, and the stringent requirements provide a benchmark for veterinary drug safety and efficacy in the animal for which it is being developed. Veterinarians can prescribe with confidence knowing they are providing optimal care to their patients and their owners. Non-approved alternatives do not have the same requirements.

Adequan Canine FDA requirement comparison chart

Discover if Adequan® Canine is the right choice.

Key facts to know

Drug Med Icon

Supplements:
The FDA states that supplements are not intended to treat, diagnose, prevent or cure disease.2 Supplements should not make direct medical claims such as "reduces pain."

Drug Med Icon

NSAIDS:
While NSAIDs are FDA approved drugs for use in dogs, none of the current non-steroidal anti-inflammatory drugs available today are approved as disease-modifying osteoarthritis drugs. They are only approved to help manage the pain associated with osteoarthritis inflammation.

Adequan® Canine Polysulfated Glycosaminoglycan Sterile Injection 100 mg/mL
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997
2. www.fda.gov -assessed 9/21/2018
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
All trademarks are the property of American Regent, Inc.
© 2022, American Regent, Inc.
PP-AC-CA-0003 (v3.0)